THE AQUALUNG THERAPEUTICS MISSION:

To provide an immune-focused biologic platform for serious inflammatory and fibrotic disorders

BREAKING NEWS

BREAKING NEWS

First Patient Enrolled in the PUERTA Phase 2A ARDS Clinical Trial: Treatment with Aqualung Therapeutics ALT-100 mAb

Aqualung Therapeutics is a Tucson, AZ and Jupiter, FL -based biotech company that has:

❖ Identified eNAMPT (extracellular nicotinamide phosphoribosyltransferase) as a key DAMP and upstream activator of  inflammatory and fibrosis cascades

❖ Developed ALT-100 mAb, a novel, anti-eNAMPT, anti-inflammatory and anti-fibrotic monoclonal antibody

❖ Developed the “eNamptor™ Platform” strategy (mAb, biomarker, genotype) for serious inflammatory, fibrotic and autoimmune disorders

❖ Published peer-reviewed work demonstrating the efficacy of the ALT-100 mAb in preclinical models of ARDS/VILI, Radiation-Induced Lung Injury/Fibrosis, Organ Fibrosis (Lung, Liver, Heart,  colon), Pulmonary Hypertension, Systemic Lupus Vasculitis,  Chorioamnionitis (associated with premature births), Prostate Cancer

About Us

Message from our CEO and Founder

As a pulmonologist and critical care physician, I have treated numerous patients, both in the outpatient arena and in the Intensive Care Unit, with life-threatening lung inflammation and progressive fibrosis. This has led me over the course of my career as a physician scientist to focus my research on understanding the mechanisms underlying uncontrolled inflammation and fibrosis with the hope of finding novel solutions as effective therapies remain an unmet need.

The scientific underpinnings of Aqualung Therapeutics began with our functional genomics studies at Johns Hopkins University which led us to identify the protein eNAMPT as a dramatically potent and novel driver of “unchecked inflammation” in a variety of specific inflammatory conditions and to initiate progression to organ fibrosis. All these conditions share a common thread; they are unmet medical needs that require novel therapies. Since this early seminal observation, Aqualung Therapeutics has developed the eNamptor™ platform containing ALT-100, our humanized monoclonal antibody that binds and neutralizes eNAMPT, as well as complementary biomarker and genotyping assays which allow us to select patients who are most likely to respond to ALT-100 mAb therapy. This is an exciting time for Aqualung as we look to take this platform technology into rigorous clinical trials to reduce inflammation, reduce fibrosis and save lives. Please join us on this exciting journey as we strive to achieve incredible milestones over the coming months and years which will improve human health.

Joe “Skip” G.N. Garcia, MD

FOUNDER AND CHIEF EXECUTIVE OFFICER

ALT-100 Indications

Acute Respiratory Distress Syndrome (ARDS)

Inflammatory Bowel Disease

Chorioamnionitis

NASH and Hepatic Fibrosis

Idiopathic Pulmonary Fibrosis

Prostate Cancer

Pulmonary Hypertension

Radiation Induced Lung Injury

Systemic Lupus Erythematosus

Aqualung in

the News

From Pipeline to Commercialization - with Stan Miele

Stan discusses the ongoing development of AQUALUNG THERAPEUTICS CORP., challenges faced by startups, clinical development and Interactions with the FDA on the road to clinical trials.

  • First Patient Enrolled in the PUERTA Phase 2A ARDS Clinical Trial: Treatment with Aqualung Therapeutics ALT-100 mAb

  • Aqualung Therapeutics Receives FDA Clearance To Proceed With the P2A PUERTA Study in Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Patients

  • Aqualung Therapeutics awarded the AZBio 2022 Fast Lane Award

  • Aqualung Therapeutics Corp. Awarded $4.8M Dollars From National Institute of Health (NIH) To Develop the ALT-100 Monoclonal Antibody for Pulmonary Arterial Hypertension and Inflammatory Bowel Disease

  • Aqualung Therapeutics Receives the AZ-Bio Fast Lane Award and Achieves Key FDA-Related Milestones

  • Aqualung Therapeutics Appoints Two New Board Directors & Will Attend June 22 Bio Meeting in San Diego

COVID News

  • Aqualung Takes Genomic Approach to COVID-19’s Killer Lung Inflammation

    Acute respiratory distress syndrome is one of the prime causes behind the mounting global death toll of COVID-19, but there are currently no FDA-approved treatments.

  • Científicos trabajan en la lucha contra el COVID-19

    Dr, Joe GN Garcia, is interviewed on the fight against COIVD-19

  • El Covid-19: un futuro impredecible para la humanidad

    Seven years ago, Dr. Joe GN “Skip” Garcia, MD, a physician-scientist, health administrator, academic, and professor of medicine at the University of Arizona School of Medicine – Tucson, sounded the alarm bells regarding to racial disparity in respiratory care in the United States.

Get in touch

Please contact us if you are interested in “learning more” or seeking an investor presentation.